Search
Odanacatib
go.drugbank.com/drugs/DB06670InvestigationalOdanacatib is an inhibiter of cathepsin K which was originally developed be Merck & Co as a new treatment for osteoporosis [A19388]. … The drug made it to phase III trials before abandoned due to increased stroke.
Brifentanil
go.drugbank.com/drugs/DB09172ExperimentalIllicitThe effects of brifentanil are very similar to those of alfentanil, with strong but short lasting analgesia and sedation, and particularly notable itching and respiratory depression.
SB-249553
go.drugbank.com/drugs/DB05285ExperimentalIt is also under by GlaxoSmithKline to treat melanoma and lung cancer.
ONT-093
go.drugbank.com/drugs/DB14069ExperimentalIn pre-clinical studies, ONT-093 could inhibit P-gp and reverse multidrug resistance at nM concentrations with no effect on paclitaxel pharmacokinetics.
ATX-201
go.drugbank.com/drugs/DB05765InvestigationalIt is developed by Kythera Biopharmaceuticals, Inc. for the treatment of actinic keratosis. The company announced the decision to discontinue its ATX-201 clinical program for actinic keratosis. … The Company determined that the program was not meeting their expected primary and exploratory objectives.
Col-118
go.drugbank.com/drugs/DB05778InvestigationalIt is a believed to reduce erythema by constricting enlarged blood vessels in facial tissue. … COL-118, a topical compound based on the SansRosa technology, for the treatment of redness associated with rosacea and other skin disorders.
XEN-D0101
go.drugbank.com/drugs/DB06020ExperimentalXEN-D0101 is an investigational drug developed by Xention Inc. for the treatment of Atrial Fibrillation. XEN-D0101 works by being a selective antagonist of the voltage-gated potassium channel Kv1.5.
Zinc sulfate, unspecified form
go.drugbank.com/drugs/DB14548ApprovedZinc sulfate is a common zinc supplement in parenteral nutrition.
Mixtures: Up and Up Ultra Itchy ReliefBasiliximab
go.drugbank.com/drugs/DB00074ApprovedInvestigationalknown as CD25 antigen) on the surface of activated T-lymphocytes. … and mouse heavy and light chain variable region genes encoding the RFT5 antibody that binds selectively to the IL-2R alpha.
NOX-700
go.drugbank.com/drugs/DB05464ExperimentalNOX-700, an new orally active dithiocarbamate-based nitric oxide (NO) blocking agent that is in development for the treatment of diabetes mellitus (type 2 diabetes). … Immunohistochemical studies on pancreatic tissue also showed that NOX-700 therapy effectively preserved islet structure and increased insulin immunoreactivity.